Skip to main content
Premium Trial:

Request an Annual Quote

Biosite Receives Revised Letters from Inverness' Financial Backers

NEW YORK (GenomeWeb News) — Biosite yesterday received another set of revised commitment letters from Inverness Medical Innovations’ proposed financing sources related to Inverness’ offer to buy the diagnostics company for $90 a share, the company said today.
 
Inverness initially sent Biosite the commitment letters on April 4, then submitted a revised set of letters earlier this week.   
 
Biosite today filed the complete set of yesterday’s commitment letters with the US Securities and Exchange Commission. The letters are being filed as exhibits relating to its “pending merger agreement with Beckman Coulter,” which offered to buy Biosite for $85 a share.
  
That bid was cleared by the Federal Trade Commission earlier this week.
 
Biosite said on April 10 that its agreement with Beckman “remains in effect,” although it has been meeting with Inverness to discuss and examine their offer.
  
Scott Garrett, Beckman’s CEO, has questioned the firmness of Inverness’ financing commitments, saying they contain “remarkably broad conditions and contingencies.
The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.